(Q40144102)

English

Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research.

scientific article published on 26 March 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17442466%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17442466%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

phase I clinical trial

0 references

Plasmodium falciparum

0 references

0 references

membrane protein

1 reference

based on heuristic

inferred from title

Arnoldo Barbosa

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17442466%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

W Ripley Ballou

22

object named as

W Ripley Ballou

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17442466%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Opokua Ofori-Anyinam

20

object named as

Opokua Ofori-Anyinam

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17442466%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Marie-Claude Dubois

19

object named as

Marie-Claude Dubois

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17442466%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

D. Gray Heppner

23

object named as

D Gray Heppner

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17442466%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

author name string

Mark E Polhemus

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17442466%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Alan J Magill

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17442466%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

James F Cummings

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17442466%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Kent E Kester

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17442466%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Chris F Ockenhouse

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17442466%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

David E Lanar

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17442466%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Sheetij Dutta

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17442466%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Lorraine Soisson

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17442466%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Carter L Diggs

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17442466%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Sally A Robinson

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17442466%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

John D Haynes

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17442466%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

V Ann Stewart

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17442466%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Lisa A Ware

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17442466%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Clara Brando

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17442466%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Urszula Krzych

16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17442466%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Robert A Bowden

17

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17442466%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Joe D Cohen

18

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17442466%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Els De-Kock

21

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17442466%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

language of work or name

0 references

publication date

26 March 2007

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17442466%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17442466%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

25

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17442466%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

21

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17442466%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

4203-4212

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17442466%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

A role for apical membrane antigen 1 during invasion of hepatocytes by Plasmodium falciparum sporozoites

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.012

7 January 2021

Transcription status of vaccine candidate genes of Plasmodium falciparum during the hepatic phase of its life cycle

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.012

7 January 2021

Integral membrane protein located in the apical complex of Plasmodium falciparum

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.012

7 January 2021

Longitudinal study of natural immune responses to the Plasmodium falciparum apical membrane antigen (AMA-1) in a holoendemic region of malaria in western Kenya: Asembo Bay Cohort Project VIII.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.012

7 January 2021

High prevalence of natural antibodies against Plasmodium falciparum 83-kilodalton apical membrane antigen (PF83/AMA-1) as detected by capture-enzyme-linked immunosorbent assay using full-length baculovirus recombinant PF83/AMA-1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.012

7 January 2021

Human antibodies to recombinant protein constructs of Plasmodium falciparum Apical Membrane Antigen 1 (AMA1) and their associations with protection from malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.012

7 January 2021

High levels of serum antibodies to merozoite surface protein 2 of Plasmodium falciparum are associated with reduced risk of clinical malaria in coastal Kenya

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.012

7 January 2021

Protection against experimental P falciparum malaria is associated with short AMA-1 peptide analogue alpha-helical structures.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.012

7 January 2021

Vaccination of monkeys with recombinant Plasmodium falciparum apical membrane antigen 1 confers protection against blood-stage malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.012

7 January 2021

A human phase 1 vaccine clinical trial of the Plasmodium falciparum malaria vaccine candidate apical membrane antigen 1 in Montanide ISA720 adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.012

7 January 2021

High-Level Expression of the Malaria Blood-Stage Vaccine Candidate Plasmodium falciparum Apical Membrane Antigen 1 and Induction of Antibodies That Inhibit Erythrocyte Invasion.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.012

7 January 2021

Induction of parasite growth-inhibitory antibodies by a virosomal formulation of a peptidomimetic of loop I from domain III of Plasmodium falciparum apical membrane antigen 1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.012

7 January 2021

Fusion of two malaria vaccine candidate antigens enhances product yield, immunogenicity, and antibody-mediated inhibition of parasite growth in vitro

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.012

7 January 2021

Enhancement of functional antibody responses to AMA1-C1/Alhydrogel, a Plasmodium falciparum malaria vaccine, with CpG oligodeoxynucleotide

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.012

7 January 2021

Malaria vaccines in development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.012

7 January 2021

Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.012

7 January 2021

Purification, characterization, and immunogenicity of the refolded ectodomain of the Plasmodium falciparum apical membrane antigen 1 expressed in Escherichia coli

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.012

7 January 2021

Development of RTS,S/AS02: a purified subunit-based malaria vaccine candidate formulated with a novel adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.012

7 January 2021

A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.012

7 January 2021

Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.012

7 January 2021

Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.012

7 January 2021

Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.012

7 January 2021

Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.012

7 January 2021

Mode of action of invasion-inhibitory antibodies directed against apical membrane antigen 1 of Plasmodium falciparum

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.012

7 January 2021

Invasion-inhibitory antibodies inhibit proteolytic processing of apical membrane antigen 1 of Plasmodium falciparum merozoites

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.012

7 January 2021

Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.012

7 January 2021

In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.012

7 January 2021

CD4+ T cells acting independently of antibody contribute to protective immunity to Plasmodium chabaudi infection after apical membrane antigen 1 immunization.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.012

7 January 2021

Allele specificity of naturally acquired antibody responses against Plasmodium falciparum apical membrane antigen 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.012

7 January 2021

Dynamics of polymorphism in a malaria vaccine antigen at a vaccine-testing site in Mali

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.012

7 January 2021

The ears of the hippopotamus: manifestations, determinants, and estimates of the malaria burden

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.012

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40144102&oldid=1749494163"